Document is current
Any future updates will be listed below
-
Authors
Valdez Capuccino, L.
Kleitke, T. https://orcid.org/0009-0007-6288-7216
Szokol, B.
Svajda, L.
Martin, F. https://orcid.org/0000-0002-3496-9093
Bonechi, F.
Krekó, M.
Azami, S.
Montinaro, A. https://orcid.org/0000-0002-2289-9374
Wang, Y.
Nikolov, V.
Kaiser, L. https://orcid.org/0000-0002-3212-576X
Bonasera, D.
Saggau, J.
Scholz, T.
Schmitt, A.
Beleggia, F. https://orcid.org/0000-0003-0234-7094
Reinhardt, H. C.
George, J.
Liccardi, G. https://orcid.org/0000-0002-2662-1281
Walczak, H.
Tóvári, J.
Brägelmann, J. https://orcid.org/0000-0002-1306-2169
Montero, J.
Sos, M. L.
Őrfi, L.
Peltzer, N. https://orcid.org/0000-0002-4134-5852
- License Information
-
More Information
Article History
Received: 13 November 2023
Revised: 22 April 2024
Accepted: 7 May 2024
First Online: 20 May 2024
Competing interests
: Authors declare no conflict of interest. BS, MK are employees of Vichem and LO is the CEO of Vichem Chemie Research Ltd. RHC received consulting and lecture fees from Roche, Novartis, BMS, Abbvie, AstraZeneca, Vertex and Merck; RHC received research funding from Gilead Sciences and AstraZeneca and is a co-founder of CDL Therapeutics GmbH. MJ is co-inventor of dynamic BH3 profiling (patented by Dana-Faber Cancer Institute) and has received royalties, he was a paid consultant for Oncoheroes Biosciences and Vivid Biosciences, is an unpaid board member for The Society for Functional Precision Medicine, and he is currently collaborating with AstraZeneca.
: Animal experiments from Fig. and Supplementary Fig. and Supplementary Fig. were approved by the local authorities (LANUV, North-Rhine-Westphalia, Germany) and performed under licence number 81-02.04.2019.A491. Animal Experiment from Fig. and Supplementary Fig. were conducted at the Department of Experimental Pharmacology, National Institute of Oncology (Budapest, Hungary). The animals used in these studies were cared for according to the “Guiding Principles for the Care and Use of Animals” based upon the Helsinki declaration, and they were approved by the local ethical committee. The animal housing density was according to regulations and recommendations from directive 2010/63/EU of the European Parliament and of the Council of the European Union on the protection of animals used for scientific purposes. Permission licence for breeding and performing experiments with laboratory animals: PEI/001/1738-3/2015 and PE/EA/1461–7/2020. All people involved in animal experiments received prior training and have passed the additional required personal licensing course (FELASA-B). All animal experiments were conducted in compliance with international and institutional ethical guidelines on animal welfare and measures to minimise animal suffering.
